news
. . .
Investors Champion Modality.AI Technology That ‘Self-Drives’ Neurological and Psychiatric Assessments
August 31, 2021
Modality.AI, pioneering AI technology for assessing neurological and psychiatric conditions remotely and in clinical settings through speech and facial measurements, has received a $2.1 million seed round led by the Relentless Venture Fund (“Relentless”), with major funding from Novalis Biotech Acceleration (“Novalis”), alongside several other funds and private investors.
Read more in the press release
. . .
Relentless Pursuit Venture Fund adds Modality.AI to its portfolio
August, 2021
Brenda Irwin, Managing General Partner at Relentless Venture Fund, writes in a LinkedIn post, "Thrilling new addition to the Relentless Venture Fund portfolio just announced."
Read more from the Relentless Partners press release
. . .
Modality.AI integrated in APST's ALS app
June, 2021
Modality.AI, developers of multimodal remote patient monitoring solutions for neurologic conditions, is pleased to announce a partnership with APST (Ambulanzpartner Soziotechnologie GmbH).
Commenting on the launch, CEO and Founder David Suendermann-Oeft said: “2020 was a pivotal year for diagnostic and remote patient monitoring solutions. Without the need for software installation or hardware purchase, Modality's conversational AI system can accurately, frequently, and objectively analyze and track patients’ data through facial and speech patterns. Modality's system frees up physicians' time by administering asynchronous tests, while collecting accurate data for the physician to use, reducing the need for manual annotation.”
The ALS App is currently available to German language speakers facilitating the capturing of the ALS Functional Rating Scale-revised (ALS-FRS) on smartphones, iPhones and tablets. Further information can be found here.
. . .
Human Behavior Club HEALTHTECH chat
April 16, 2021
David Fox, Chief Business Officer and David Suendermann-Oeft, CEO and Founder of Modality.AI, will speak at the Human Behavior Club
the largest club on Clubhouse w/ 25k members and 400k followers
live on Friday, April 16, 12 noon PT
organized by Charm Health
. . .
Healthtech Award Winner: The Story of Modality.AI
March 29, 2021
HealthTech Networking Club member and winner of the HealthTech Startup Award in January, David Suendermann-Oeft, CEO and Founder of Modality.AI, spoke with the bene : studio team about what inspired him to start the company, their biggest achievements so far, and advice for startup leaders in the digital health space.
. . .
Modality.AI presentations this month
March 2021
It has been a busy month here at Modality. Last week, we were one of the youngest companies to present at the Landmark Health Innovations Forum 2021 sponsored by MorganStanley and NIH.
. . .
Modality.AI also presented at Life Science Nation's Innovator's Pitch Challenge RESI Conference Investor's Pitch Challenge, in March, 2021.
It has just been announced that Modality.AI was awarded Second Place in the Investor's Pitch Challenge. We are thrilled that the #RESI community thinks so highly of our groundbreaking technology and accomplishments! Thank you for the opportunity to present at the event. We look forward to future #RESI and @LSciNation conferences.
https://twitter.com/LSciNation/status/1374449472546074624?s=20
. . .
And Modality.AI was selected to present at the Startup Springboard in partnership with BIO-Europe Spring, Europe's largest springtime digital partnering event, March 22-25, 2021.
. . .
Modality.AI presents paper at April 2021 American Academy of Neurology Meeting
February 2021
We are pleased to announce that our work titled "Towards a large-scale audio-visual corpus for research on Amyotrophic Lateral Sclerosis" in collaboration with @everything_als, @MITdeptofBE, @harvardbrainsci and @IBMResearch will be presented at this year's virtual #AANAM .
https://www.aan.com/conferences-community/annual-meeting/
. . .
Modality.AI wins Healthcare Startup Award
January 2021
"Modality.AI was chosen as the winner of the monthly HealthTech Startup Award after pitching alongside 4 other startups in January 2021.
The session was moderated by Sandra Miller (Runway Innovation Hub). Judges Roger Kuo (GoingVC), Dr. Orrin Ailloni-Charas (Global Health Impact Fund), Dr. Gary Goldman (GHIF), Michael Koutsoudakis (Paulson Investment Company), and Balint Bene (bene : studio) awarded this month’s prestigious title."
https://benestudio.co/healthtech-startup-award-january-2021-modality/
. . .
Modality.AI presents at 2021 Biotech Showcase
January 5, 2021
Modality.AI, developers of multimodal remote patient monitoring solutions for neurologic conditions, presented at the Seed Showcase, part of the Biotech Showcase, held between January 11-14 2021. Prof. Dr. David Suendermann-Oeft, Founder and CEO presented. Please contact David Fox david.fox@modality.ai or search “Modality.AI” in the partneringONE platform to book a meeting.
Commenting on the event, Suendermann-Oeft said: “2020 has been a pivotal year for diagnostic and remote patient monitoring solutions. Without the need for software installation or hardware purchase, Modality's conversational AI system can accurately, frequently, and objectively analyze and track patients’ data through facial and speech patterns. Modality's system frees up physicians' time by administering asynchronous tests, while collecting accurate data for the physician to use, reducing the need for manual annotation.”
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
“We were delighted to see Modality.AI raise funding at the 2020 Seed Showcase,” said Lila Taylor, CBO of Demy-Colton. “We created the Seed Showcase to bring early-stage life science entrepreneurs and investors together to accelerate the development of innovative technologies that will drive the future of drug discovery.”
. . .
Artificial intelligence taking role in developing technology to help Parkinson’s patients during COVID-19 pandemic
November, 2020
Jessica Huber, a professor of speech, language, and hearing sciences and associate dean for research in Purdue’s College of Health and Human Sciences, leads Purdue’s Motor Speech Lab. Huber and her team are now doing virtual studies to evaluate speech disorders related to Parkinson’s using artificial intelligence technology platforms.
Huber and her team have been working to develop telepractice tools for the assessment and treatment of speech impairments like Parkinson’s disease. They received a National Institutes of Health small business innovation and research grant to develop a telehealth platform to facilitate the provision of speech treatment with the SpeechVive device, which has received attention at the Annual Convention of the American Speech-Language-Hearing Association.
In the current study, Huber and her team are collaborating with a startup company, Modality AI, which developed the AI platform that will be used in the study.
“The application of the technology we are evaluating may lead to far-reaching insights into more standardization in assessments, earlier diagnoses and possibly an easier way to track discrete changes over time to guide interventions,” said Andrew Exner, a graduate research assistant in the Motor Speech Lab. “My personal research passion, and the mission of our lab, is to find ways to improve the quality of life for people with Parkinson’s and other related diseases.”
. . .
Modality Names Tom Sellig to Board of Advisors
April 8, 2020
Modality, a pioneer in AI-backed healthcare screening solutions, announced that it has named Tom Sellig to its Board of Advisors. Mr. Sellig is Chief Executive Office of LabConnect, a leading global provider of central laboratory and support services for biopharmaceutical, pharmaceutical, medical device, and contract research organizations. He also sits on its Board of Directors.
“We are pleased to welcome Tom to Modality,” said David Suendermann-Oeft, Cofounder and Chief Executive Officer of Modality. “His experience in the clinical research space, as well as broader medical technology landscape, will be a tremendous value in helping us optimize how data is collected and used in the research and treatment development process.”
Added Mr. Sellig, ”What Modality is doing with facial and voice recognition data in its AI-powered screens to improve research outcomes is vitally important and highly needed. The cleaner the data, the more accurate the results – and I am excited to join David and his team in delivering that to a wide range of opportunities in digital health today.”
Prior to joining LabConnect, Mr. Sellig served as Chief Commercial Officer at ConnectiveRx and from 2014 to 2018, he was Senior Vice President of Global Sales at Patheon, which was acquired by Thermo Fisher Scientific in 2017. From 2007 to 2014, he held a variety of roles of increasing responsibility within global contract research organization and drug development services company Covance. Before Covance, he had executive leadership roles at Ventana Clinical (now part of Syneos) and Medical Broadcasting Company. He earned his bachelor's degree in Economics from Vanderbilt University and an MBA from New York University.
. . .
Modality Names Four to Board of Advisors
January 22, 2020
Modality named four leading professionals in the medical and healthcare industries to its board of advisors:
Dr. Jordan Green, Matina Souretis Horner Professor in Rehabilitation Sciences and Director of Speech and Feeding Disorder Lab and Associate Provost of Research at the MGH Institute of Health Professions at Harvard University
Dr. Harneet Bath, Vice President of Inpatient Services at VEP Healthcare
Dr. Gloria Lau, CEO and cofounder of Alpha Medical
Dr. Irfan Qureshi, Vice President at Biohaven Pharmaceuticals
“Modality is delighted to have such a distinguished group of professionals join our advisory board. Their collective expertise will synergistically help Modality’s automatic speech and facial analytics capabilities to expedite drug trials, reduce the failure rate of trials, and increase the profitability of drugs,” said Dr. David Suendermann-Oeft, CEO and co-founder of Modality. “Their commitment to Modality further confirms the value that we provide to the clinical research space and to the pharmaceutical industry.”
. . .
Modality is featured as one of the five conversational AI companies in the Tooploox AI Trend Report
January, 2020
www.tooploox.com/ai-trend-report-2020/files/AI_Trend_Report_2020_Tooploox.pdf
. . .
Modality.AI's first VC visits the office
January 22, 2020
Voxel Ventures, a Digital Health fund from Frankfurt, Germany, and the first VC to invest in Modality, visited us January 22, 2020 at the San Francisco Office.
Voxel Ventures' Julian Wichmann, Startup Investor & Advisor and Radiologist, MD, said,
"Great meeting yesterday here in San Francisco with the Modality.AI team (a Voxel Ventures portfolio company).
So their fully functional software platform is able to analyze your voice and facial movement in real time, allowing for clinical assessment from home! I tried it out myself and was impressed by the flawless and smooth integration - all you need is a web browser, camera, and internet access (=mobile friendly)! Their #artificialintelligence software is already being tested in clinical trials at a major university hospitals, in which patients with severe neurological diseases can be evaluated at their own pace from home with much more and better data being generated - at a fraction of the cost! Obviously the use cases and business cases for such a system in the future are endless!
True innovation that really helps patients and advances the field is unfortunately hard to find in my opinion when you‘re in #digitalhealth or #healthcare #venturecapital and most #startups often only have an idea for a product. Modality.AI and its brilliant team stood out to me from the beginning and I‘m very excited about their progress and big news in 2020!"
. . .
Modality Announces UCSF Partnership
September 20, 2019
Modality announced its partnership with the University of California, San Francisco’s Weill Institute of Neurosciences at the Alchemist Accelerator’s demo day in Menlo Park on September 20, 2019. Under the terms of the partnership, UCSF researchers are using Modality to help streamline their research process and optimize data collection and analysis.
“We just started using Modality to collect our data, and we can already see it saving us a great deal of time while collecting accurate information,” said Dr. Carly Demopoulos, Assistant Professor of Psychiatry at the Weill Institute. “Our research has become vastly more efficient and I’ve already started planning future studies that are made feasible by Modality.”
View a video from Demo Day. [https://vimeo.com/362379517]
Dr. Dempoulos and her team study autism spectrum disorder, particularly characterizing the pathology’s underlying symptoms in order to develop targeted therapies. Autism affects more than 60 million people globally.
Traditionally in research, patients and their caregivers need to go to the lab for interviews, from which speech behaviors are manually recorded, analyzed, and categorized. This has historically been a very cumbersome and labor-intensive process.
“The underlying process to develop drugs and therapies are extremely inefficient,” said David Suendermann-Oeft, CEO and co-founder of Modality. Presently, drug trials take on average six years to complete, according to data from Johns Hopkins University, with 80% failing to secure FDA approval and a spend of roughly $70 billion a year.
“Modality has created a solution,” Dr. Suendermann-Oeft said. “We have created a neurological test that is based on the principle that engages the patient with an avatar in a conversation using the same protocols that the neurologist is using. We are extracting facial movements and speech patterns and producing in real time accurate metrics that are predictive of the clinical outcome.”
As a result, Modality can help close the trials four months earlier, reduce the failure rate by 15%, and increase return on investment in a drug’s investment by 80%.
. . .
. . .
